On September 30, 2025 Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, reported that its management will participate in the second annual Oncology Venture, Innovation, and Partnering Summit being held September 29-30, 2025, at the Westin Boston Seaport in Boston, MA (Press release, Calidi Biotherapeutics, SEP 30, 2025, View Source [SID1234656341]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Eric Poma, Ph.D., Chief Executive Officer, will participate in a fireside chat with Dr. Aydin Huseynov, Managing Director and Senior Analyst at Ladenburg Thalmann, on the intersection of science and capital to develop and advance effective cancer treatments on September 30, 2025, at 10:10 a.m. E.T. Dr. Poma’s presentation will highlight Calidi’s RedTail platform, which is engineered to protect virus from immune clearance and induce tumor lysis and deliver potent therapeutic genetic medicines to metastatic sites through systemic administration.

Dr. Poma will be available to participate in one-on-one meetings with participants registered to attend the conference.